Objective-Macrophage (Mϕ) migration rests on the adhesion/detachment between Mϕ surface components and extracellular matrixes, and the contribution of numerous inflammatory disorders. Plasminogen activator inhibitor (PAI)-1, a serine protease inhibitor, influences Mϕ motility through an action distinct from its classical modulation of the plasmin-based fibrinolytic process. We rely here on a small molecule PAI-1 inhibitor (TM5275) to investigate the role of PAI-1 in Mϕ migration in the pathogenesis of renal injury. Approach and Results-Mϕ migration was inhibited both in vitro and in vivo by TM5275. It was also reduced in T-celldeficient nude mice, but not in PAI-1-deficient mice. Mϕ migration hinged on the interaction of PAI-1 with low-density lipoprotein receptor-related protein, an interaction prevented by TM5275, but not with vitronectin, urokinase-type plasminogen activator, or tissue-type plasminogen activator. Fed to rats with anti-Thy-1-induced nephritis, TM5275 significantly decreased Mϕ accumulation and ameliorated the progression of renal injury.
T he fibrinolytic system not only removes fibrin deposits from the vasculature, but is also implicated in extracellular matrix remodeling. [1] [2] [3] The primary fibrinolytic enzyme, plasmin, is a potent, broadly acting serine protease, formed when circulating plasminogen is cleaved and activated by 1 of 2 plasminogen activators, tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). The serine protease inhibitor plasminogen activator inhibitor (PAI-1) is the main plasma inhibitor of uPA and tPA. It inhibits plasmin-mediated fibrinolysis. 4 Interestingly, recent studies in mice deficient in or overexpressing the PAI-1 gene implicate that, in addition to its original action on the fibrinolytic process, PAI-1 is involved in several broad biological abnormalities, such as fibrosis, cell regeneration, and metabolic or neurological disorders. 5, 6 More recently, PAI-1 has been shown to affect significantly on cell adhesion, detachment, and migration by an interaction with various molecules, such as tPA, uPA, vitronectin (VN), and low-density lipoprotein receptor-related protein (LRP). [7] [8] [9] Indeed, genetic inactivation of PAI-1 or LRP1 can reduce macrophage (Mϕ) migration 10 and ameliorate inflammatory or allergic diseases in rodents.
We have developed an original approach to identify and synthesize orally active inhibitors of PAI-1. Compounds selected virtually by structure-based drug design underwent a docking simulation to select candidates that fit within the cleft accessible to insertion of the reactive center loop comprising s3A in PAI-1 3-dimensional structure. These compounds have been shown to inhibit coagulation in 2 different rodent models and 1 monkey model of thrombosis, and prevent the fibrotic process in 2 different rodent models of lung fibrosis. 11 In this study, we use such a newly developed small molecule PAI-1 inhibitor, TM5275, as a chemical probe and investigate the effect of the inhibitor on Mϕ function, such as migration and cytokine secretion. We demonstrate that PAI-1 functions as a chemotactic factor and attracts Mϕ in vivo and in vitro, an action effectively prevented by the PAI-1 inhibitor TM5275. On closer inspection, Mϕ migration hinges on the interaction of PAI-1 with LRP, but not with VN, uPA, or tPA. TM5275 inhibits Mϕ migration in vitro by preventing the interaction between PAI-1 and LRP, and TM5275 also prevents Mϕ migration in vivo. Given to a rat Thy-1 nephritis model, TM5275 significantly decreases the number of infiltrated Mϕ and ameliorates the progression of renal injury. This small molecule PAI-1 inhibitor is thus a novel class of antiinflammatory agent targeting Mϕ migration.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

TM5275 Inhibits Mϕ Migration Into the Peritoneum
The effect of TM5275 on in vivo Mϕ migration was investigated. Mϕ migration into the mouse peritoneum was induced by the intraperitoneal injection of a thioglycollate solution for 4 days. Mice with or without TM5275 were used for an in vivo assay. After 4 days, the PAI-1 level increased significantly in the peritoneal fluid ( Figure 1A ) of control mice but fell significantly (P<0.01) in those given TM5275. Results were compared with dexamethasone (corticosteroid), a well-known inhibitor of Mϕ migration, 12 and with clopidogrel, an analog of ticlopidine that inhibits adenosine diphosphate-mediated platelet aggregation. TM5275 as well as dexamethasone, but not clopidogrel, inhibited Mϕ migration in a dose-dependent manner in vivo ( Figure 1B ). To confirm that TM5275 inhibited Mϕ migration through its interaction with a PAI-1 moiety, we performed the same experiment in PAI-1-deficient mice and their wild-type littermate controls. As expected, quantitative Mϕ accumulation in PAI-1-deficient mice was significantly reduced as compared with wild-type mice, whereas TM5275 failed to inhibit Mϕ infiltration ( Figure 1C ), indicating that the PAI-1 modulates Mϕ migration.
Is TM5275-mediated inhibition of Mϕ infiltration a direct effect on Mϕ or an indirect effect through other immune cells, such as inflammatory T-cells known to activate Mϕ? 13 TM5275 was therefore tested in T-cell-deficient nude mice. It inhibited Mϕ infiltration into the peritoneum, despite the absence of T-cells ( Figure 1D ), indicating that at least T-cells are not required for the PAI-1-induced Mϕ migration.
Taken together, these data suggest that PAI-1 facilitates Mϕ migration in vivo in the peritoneum of mice given thioglycollate. This effect is effectively prevented by a PAI-1 inhibitor TM5275.
PAI-1 Induces Mϕ Migration Via LRP
The benefit of TM5275 on the Mϕ migration was tested in vitro in a modified Boyden chamber with a human acute monocytic leukemia cell line, THP-1, which differentiates into Mϕ-like cells on incubation for 2 days with 50 nmol/L phorbol 12-myristate 13-acetate, (PMA). TM5275 inhibited the PAI-1-induced THP-1 migration in a dose-dependent manner (Figure 2A ). By contrast, it proved ineffective for the THP-1 migration induced by the fetal bovine serum, which contained matrix components, such as VN and fibronectin, all factors known to affect Mϕ migration as chemoattractants ( Figure 2B ). These results suggest that TM5275 inhibits only PAI-1-dependent Mϕ migration.
Several candidate proteins for Mϕ migration, for example, tPA, uPA, VN, and LRP, were investigated to elucidate the molecular mechanism(s) underlying the THP-1-derived Mϕ migration. We used endotoxin-free PAI-1 mutants, that is, PAI-1 R76E (a mutant with no interaction with LRP), PAI-1 Q123K (a mutant with no binding ability to VN), and PAI-1 T333R (a mutant with no inhibitory activity against uPA/tPA). Among these PAI-1 proteins, only the PAI-1 R76E mutant affected Mϕ migration ( Figure 2C ), indicating that the PAI-1-induced cell migration hinges on its interaction with LRP1, whereas VN, uPA, or tPA is not necessarily required. In our assays, the expression of LRP1 mRNA and protein was very low in monocytic THP-1 cells without treatment with PMA but rose significantly after PMA treatment ( Figure 2D and 2E). PAI-1 is thus unable to induce the transmigration of monocytic THP-1 cells without previous treatment with PMA (data not shown). The critical role of LRP1 in PAI-1-induced Mϕ migration was confirmed with an LRP1 antagonist, receptor-associated protein, 9 and an LRP1 neutralizing antibody. As shown in Figure 2F and 2G, receptor-associated protein and anti-LRP1 antibody indeed inhibited PAI-1induced Mϕ migration. The inhibitory action of TM5275 on the direct molecular interaction between PAI-1 and LRP1 was further examined. Previous studies showed that PAI-1 binds both to cluster II (Cl II) and to cluster IV (Cl IV) LRP. 14, 15 LRP1 protein Cl II and Cl IV were thus immobilized on a 96-well ELISA plate, and Alexa488-labeled PAI-1 was added either in the presence or absence of 10 μmol/L TM5275 for 3 hours. The amount of PAI-1 bound to LRP1 was eventually assessed by the fluorescence intensity of Alexa488. The apparent binding of PAI-1 to LRP1 was significantly reduced by TM5275 ( Figure 3 ). Receptor-associated protein (1 μmol/L) also inhibited the binding between PAI-1 and LRP1 (Figure in the online-only Data Supplement). A dose-response analysis demonstrated that TM5275 inhibited the binding between PAI-1 and LRP1 at a much lower concentration (IC50=3.13 μmol/L and 3.02 μmol/L for Cl II and Cl IV, respectively) than that required to inhibit the PAI-1 activity (IC50=6.95 μmol/L).
The effect of TM5275 on other Mϕ functions, such as differentiation and lipopolysaccharide (LPS)-induced cytokine secretion, was investigated. Monocytic THP-1 cells were incubated with PMA either in the presence or absence of 10 μmol/L TM5275, and the expression of Mϕ-specific mRNAs F4/80, Cd68, Cd11b, Csf1r, Ccl2, Tnf, and Lrp was analyzed ( Figure 4A ). TM5275 had virtually no influence on the expression of these Mϕ marker genes. The effects of TM5275 on interleukin-6 (IL-6) secretion and NO synthesis were further tested in the THP-1-derived Mϕ because PAI-1 expression can be modulated by various cytokines. 16, 17 THP-1-derived Mϕ were stimulated either with LPS only or with LPS plus interferon-γ. Analysis of the cell culture supernatant disclosed that TM5275 had no effect on IL-6 secretion and NO synthesis ( Figure 4B and 4C).
Taken together, these data demonstrate that PAI-1 directly facilitates Mϕ migration. TM5275 effectively inhibits Mϕ migration by preventing the interaction between PAI-1 and 
TM5275 Inhibits In Vivo Mϕ Infiltration in a Rat Anti-Thy-1 Glomerulonephritis Model
The clinical benefit of TM5275 was tested in a rat model of anti-Thy-1 glomerulonephritis, which develops glomerular endo-and extracapillary lesions. In this model, the mRNA expressions of PAI-1 and Mϕ marker genes (Cd11b, Cd68) significantly increased in the kidney 6 days after induction ( Figure 5A ). Anti-Thy-1. Figure 5A ) and immunohistochemical analysis ( Figure 5B and 5C ). TM5275 provision significantly reduced ED-1 (C68) positive cells attracted in the glomerulus by the anti-Thy-1 antibody treatment.
Consistent with previous reports, 18-21 injection of anti-Thy-1 caused acute mesangiolysis, capillary ballooning, and microaneurysm formation at day 7 ( Figure 6 ). Treatment with TM5275 significantly suppressed extracellular matrix formation on day 7 as determined by Masson Trichrome staining ( Figure 6A ). Glomerular injury ( Figure 6B ) and microaneurysm formation ( Figure 6C) were also significantly suppressed. Phosphotungstic acid hematoxylin staining further revealed a reduced deposition of fibrin in the glomerulosclerotic lesions ( Figure 6D and 6E) . In normal rat kidney, staining for desmin in the podocytes was negligible, whereas staining for Wt1 was readily apparent (Figure 6F-6I) . In anti-Thy-1 antibodyinduced nephritis, increased staining of desmin and reduced expression of Wt1 were observed in the glomeruli ( Figure  6F-6I) , whereas TM5275 treatment significantly decreased desmin expression and increased Wt1 expression ( Figures  6F-6I ). Neither vehicle nor clopidogrel proved effective.
These data indicate that oral administration of TM5275 not only reduces Mϕ infiltration, but also ameliorates microaneurysm formation, mesangial proliferation, endothelial dysfunction, and podocyte injury, all this without adverse effects.
Discussion
In this study, we demonstrate that PAI-1 attracts Mϕ and functions thus as a chemotactic factor. First, in the peritoneum of mice given thioglycollate, PAI-1 is involved in vivo in Mϕ migration, as shown by a specific small molecule PAI-1 inhibitor or in PAI-1 knockout mice. At least, T-cells are not required for this effect. Second, PAI-1 is essential for the in vitro Mϕ migration, assessed in a modified Boyden chamber with a human monocytic cell line THP-1. We confirmed that the effect of PAI-1 on Mϕ migration is direct, and that PAI-1-induced cell migration hinges on its interaction with LRP1, whereas VN, uPA, or tPA is not necessarily required. The effect of PAI-1 on Mϕ migration is direct. TM5275 effectively inhibits Mϕ migration by preventing the interaction between PAI-1 and LRP1, whereas it does not affect the LPS or LPS/ interferon-γ-induced cytokine secretion and NO synthesis.
Previous studies suggested links of Mϕ migration to thrombotic sites and tPA-mediated fibrinolysis. 10, 22, 23 Cao et al 10 demonstrated that tPA, Macrophage-1 antigen (Mac-1), and LRP1 are essential for Mϕ migration. They reported that tPA promotes Mac-1-mediated adhesion, whereas PAI-1 and LRP1 facilitate Mϕ detachment from fibrin. In the present study, we also show that PAI-1 acts as a chemoattractant for Mϕ even in the absence of VN, uPA, or tPA, and that PAI-1 induces Mϕ migration through its interaction with LRP.
LRP1 is a cell surface molecule binding PAI-1. Our present observations agree with previous studies that LRP1 mediates PAI-1-induced cell migration in other type of cells, such as smooth muscle cells and microglia. 9,24 PAI-1 had no chemotactic effect on nonstimulated THP-1 cells, which are expressing low level of LRP1.
Gaultier et al 25 previously demonstrated that LRP1 deficiency in a mouse embryonic fibroblast or in a Mϕ cell line increased expressions of inflammatory mediators, such as inducible nitric oxide synthase and IL-6. Furthermore, a Mϕ-specific deletion of LRP1 in a mouse model of atherosclerosis increased production of inflammatory cytokines and exacerbated vascular lesions. 26 A lack of LRP1 signals in Mϕ enhances therefore their inflammatory activities. By contrast in our results, an in vitro blockade of PAI-1 and LRP1 interaction on Mϕ did not affect LPS-induced IL-6 production and NO synthesis. In addition, LPS-induced IL-6 production from bone marrow-derived Mϕ of PAI-1 +/+ and −/− mice were found to be comparable (data not shown). Because LRP1 recognizes at least 30 different ligands, including PAI-1, 27 the LRP-mediated Mϕ activation may vary depending on the type of LRP1 ligand that interacts with LRP.
PAI-1 expression is dramatically enhanced in inflammatory lesions of various inflammatory diseases, such as chronic kidney disease and multiple sclerosis (MS). [28] [29] [30] [31] In fact, the genetic disruption of the PAI-1 gene in mice experimental models ameliorates their process of diseases. 29, 32, 33 Inhibition of PAI-1 is thus a potentially therapeutic goal. Our present study in a rat model of anti-Thy-1 glomerulonephritis provides a clue in this direction. TM5275 treatment significantly reduced glomerular ED-1 positive cells, raised by the anti-Thy-1 antibody treatment, reduced proteinuria, and ameliorated histological injuries, such as microaneurysm formation, mesangial proliferation, endothelial dysfunction, and podocyte injury. Of note, these benefits accrue from TM5275, but not clopidogrel, administration.
Although healthy human kidneys do not express PAI-1, kidney disease leads to expression of PAI-1 in both glomeruli and tubulointerstitium. [34] [35] [36] [37] Overexpression of PAI-1 exacerbates renal fibrosis in obstructed kidneys, 38 whereas the specific disruption of the PAI-1 gene ameliorated the injury. 32 Interestingly, the attenuation of renal fibrosis in PAI-1-deficient mice with obstructive nephropathy was associated with a substantial delay in the recruitment of Mϕ in the kidney. 32 Conversely, mice that overexpress PAI-1 exhibit increased renal damage, accompanied by increased infiltration of Mϕ 38 . Indeed, not only coagulation and fibrinolysis 39 but also Mϕ infiltration 40 into the kidney itself would be a key for induction of renal damage. In agreement with our present finding, expression of a mutant, noninhibitory form of PAI-1 decreased matrix accumulation in the anti-Thy-1-induced nephritis. 41 These observations, together with our study suggest that PAI-1 is involved in chronic kidney diseases at least in part through the involvement of PAI-1 and Mϕ infiltration, supporting the contention reviewed by Ha et al 42 42 should also be considered. Involvement of PAI-1 is also implicated in neuroinflammation in MS. 30, 31 In experimental allergic encephalomyelitis, an animal model of MS, levels of PAI-1 are significantly increased in acute MS lesions. In addition, elevated serum and tissue levels of PAI-1 have been found in MS patients. 31 Of note, high levels of PAI-1 during disease relapse are associated with an increase in Mϕ infiltration. 43 The tPA-deficient mice suffer an early onset and more severe form of disease that is associated with high levels of PAI-1. 44 By contrast in the PAI-1-deficient mice, the disease incidence and clinical severity were reduced. 33 The absence of inflammatory cells in the brain from the PAI-1-deficient mice mirrored the clinical picture. Clinical benefit of PAI-1 inhibitors in MS is of interest but remains elusive.
Small molecule PAI-1 inhibitors may thus herald a novel class of anti-inflammatory agents, preventing interaction of PAI-1 and LRP1, and thus targeting Mϕ migration. Recent studies in mice deficient of or overexpressing the PAI-1 gene implicate that in addition to its original action on fibrinolysis, PAI-1 has broad biopathophysiological functions, such Figure 6 . Effects of TM5275 on macrophage (Mϕ) infiltration and kidney injury in glomerulonephritis. Thy1.1 glomerulonephritis (GN) rats were divided into 3 treatment groups: vehicle (GN+vehicle), TM5275 (30 mg/kg per day, PO; GN+TM), and with clopidogrel (CLO; 30 mg/ kg per day, PO; GN+CLO). A, Representative photomicrographs of Masson trichrome-stained kidney sections 7 days after induction of GN (original magnification ×100). Pathological score (B) and microaneurysm severity (C) were assessed by the area occupied in the glomerulus as follows: Score 1, 0% to 25%; Score 2, 25% to 50%; Score 3, 50% to 75%; Score 4, 75% to 100%. At least 50 glomeruli were randomly assessed. Representative photomicrographs of phosphotungstic acid-hematoxylin (PTAH; D), desmin (F), and Wt1 (H) stained kidney sections 7 days after induction of GN (original magnification ×400). Fifty glomeruli were observed randomly, and the area of fibrin deposition (E) by imaging analyses software, ImageJ ver. 1.440, desmin positive area (G), and the number of wild-type (WT)-1 positive cells (I) was assessed in each glomerulus and averaged. Data are expressed as the mean±SEM. †P<0.01 vs control, *P<0.05 vs GN+vehicle.
as fibrosis, cell regeneration, and inflammation. 5, 6 Small molecule PAI-1 inhibitors might thus further prove useful as tools not only to unravel these disorders but also to open new therapeutic avenues.
